Skip to main content
Premium Trial:

Request an Annual Quote

NIGMS Soliciting Applications for its Research, Teaching-Intensive Career Development Program

Premium

The National Institute of General Medical Sciences is again soliciting applications from research-intensive institutions and their partners for its Institutional Research and Academic Career Development Awards program, or IRCADA, now in its 12th year. According to the newly reissued program announcement from NIGMS, IRCADA awards provide support "for a traditional mentored postdoctoral research experience at an RII [research-intensive institution] combined with an opportunity to develop the academic skills, including teaching, through workshops and through mentored teaching assignments of postdoctoral fellows at a partner institution." Overall, the agency says, the program's primary goals are to "develop a diverse group of highly trained biomedical and behavioral scientists who have the necessary knowledge and skills to pursue research and teaching careers in academia" and to "strengthen the overall teaching and research opportunities at partner institutions, with the expectation that it would further foster the development of the next generation of a diverse pool of scientists." At the Feedback Loop blog, Shiva Singh — who heads the Special Initiatives Branch within the Division of Minority Opportunities in Research at NIGMS — says that "because the IRACDA program combines a traditional mentored research experience with instruction, it prepares scientists for careers in both research and teaching."

According to the program announcement, only one application is allowed per institution. NIGMS will begin accepting applications August 22; the deadline for submissions is 5 pm (applicant organization's local time) September 22.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.